{
    "organizations": [],
    "uuid": "5f91a1ca0cd0d50bad7ccfcdb7f471bfb0516b9c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-glycomimetics-announces-design-of/brief-glycomimetics-announces-design-of-phase-3-clinical-trial-for-gmi-1271-idUSASB0C8U7",
    "ord_in_thread": 0,
    "title": "BRIEF-Glycomimetics Announces Design Of Phase 3 Clinical Trial For GMI-1271",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - Glycomimetics Inc:\n* GLYCOMIMETICS ANNOUNCES DESIGN OF PHASE 3 CLINICAL TRIAL FOR GMI-1271 IN RELAPSED/REFRACTORY AML\n* GLYCOMIMETICS INC - PRIMARY ENDPOINT FOR SINGLE PIVOTAL CLINICAL TRIAL WILL BE OVERALL SURVIVAL\n* GLYCOMIMETICS INC - MULTIPLE CLINICAL READOUTS PLANNED STARTING YEAR-END 2018 AND THROUGH 2019 AND 2020\n* GLYCOMIMETICS INC - IN EARLY 2019, ANTICIPATE TOPLINE DATA FROM PROOF-OF-CONCEPT TRIAL OF GMI-1271 IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-06T05:16:00.000+02:00",
    "crawled": "2018-03-06T22:31:54.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "glycomimetics",
        "inc",
        "glycomimetics",
        "announces",
        "design",
        "phase",
        "clinical",
        "trial",
        "aml",
        "glycomimetics",
        "inc",
        "primary",
        "endpoint",
        "single",
        "pivotal",
        "clinical",
        "trial",
        "overall",
        "survival",
        "glycomimetics",
        "inc",
        "multiple",
        "clinical",
        "readout",
        "planned",
        "starting",
        "glycomimetics",
        "inc",
        "early",
        "anticipate",
        "topline",
        "data",
        "trial",
        "multiple",
        "myeloma",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}